- Erratum
-
- KMID: 2543956
- Blood Res.
- 2023 Jun;58(2):124-124.
- doi: 10.5045/br.2023.2022218e1
-
- CITED
-
- Close
- SHARE
-
- Close
- Overexpression of S100A9 in donor T cells is associated with reconstitution of gut microbiota and outcome of allogeneic hematopoietic stem cell transplantation
-
Kim S, Lim S, Razmkhah F, Choi J
- KMID: 2543951
- Blood Res.
- 2023 Jun;58(2):105-111.
- doi: 10.5045/br.2023.2022238
-
- CITED
-
- Close
- SHARE
-
- Close
- A case report of thrombotic thrombocytopenic purpura-like syndrome after Coronavirus disease 2019 vaccination
-
Noh S, Kim SA, Lee JY, Lee JO, Bang SM
- KMID: 2543953
- Blood Res.
- 2023 Jun;58(2):116-117.
- doi: 10.5045/br.2023.2023036
-
- CITED
-
- Close
- SHARE
-
- Close
- An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement– an illustrative report
-
Ray D, Sreedharanunni S, Balakrishnan A, Sharma P, Mallik N, Peyam S, Sachdeva MUS
- KMID: 2543955
- Blood Res.
- 2023 Jun;58(2):120-123.
- doi: 10.5045/br.2023.2023084
-
- CITED
-
- Close
- SHARE
-
- Close
- End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward
-
Patra PC, Rainchwar S, Singh R, Halder R, Mehta P, Verma M, Ahmed R, Raichaudhuri JS, Bhurani D, Agrawal N, Pramanik S
- KMID: 2543952
- Blood Res.
- 2023 Jun;58(2):112-115.
- doi: 10.5045/br.2023.2022241
-
- CITED
-
- Close
- SHARE
-
- Close
- Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report
-
Mekni S, Kanoun RY, Ladeb S, Belloumi D, Abdeljelil NB, Othman TB
- KMID: 2543954
- Blood Res.
- 2023 Jun;58(2):118-120.
- doi: 10.5045/br.2023.2023061
-
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of plasmapheresis in neutropenic patients suffering from cytokine storm because of severe COVID-19 infection
-
Sadeghi A, Sadeghi S, Peikar MS, Yazdi M, Sharifi M, Ghafel S, Khorvash F, Ataei B, Safavi MR, Nasri E
- KMID: 2543949
- Blood Res.
- 2023 Jun;58(2):91-98.
- doi: 10.5045/br.2023.2022201
Background With the emergence of the coronavirus disease 2019 (COVID-19) and inability of healthcare systems to control the disease, various therapeutic theories with controversial responses have been proposed. Plasmapheresis was administered... -
- CITED
-
- Close
- SHARE
-
- Close
- A survey evaluating hematology physiciansÊ perspectives on central nervous system prophylaxis
-
Demirci U, Yüksel MK, Kırkızlar HO, Ateşoğlu EB, Mehtap , Salim O, Demir AM, Akay OM
- KMID: 2543950
- Blood Res.
- 2023 Jun;58(2):99-104.
- doi: 10.5045/br.2023.2023066
Background Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen,... -
- CITED
-
- Close
- SHARE
-
- Close
- Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
-
Byun JM, Park SS, Yoon SS, Ahn A, Kim M, Lee JY, Jeon YW, Shin SH, Yahng SA, Koh Y, Min CK
- KMID: 2543948
- Blood Res.
- 2023 Jun;58(2):83-90.
- doi: 10.5045/br.2023.2023005
Background The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a... -
- CITED
-
- Close
- SHARE
-
- Close
